Roche Holding AG Stock News

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three buys and a bail, including Roche, TotalEnergies, AB InBev, and Arm.

Euan Munro of Newton Investment and David Roche of Independent Strategy discuss the possibility of the Federal Reserve reducing interest rates against the backdrop of high government spending and budg

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite

David Roche, president and global strategist at Independent Strategy, says China may be stagnating, but it's "stagnating at a later stage of development than India."

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

Roche is considering selling its lung disease drug Esbriet, Bloomberg News reported on Monday citing people with knowledge of the matter.

David Roche, president and global strategist at Independent Strategy, says the market expects artificial intelligence to "revolutionize productivity" in the U.S. economy, but that narrative will event

Xolair, a 20-year-old asthma drug sold by Roche and Novartis , significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sun

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Roche is a well-recognized pharmaceutical company with a strong international presence and a market capitalization of CHF 187 billion. Despite recent challenges, Roche's 2024 guidance shows potential

Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.

Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.